Drug Trial Radar · NCT07799532
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Jul 2027
Study completion Dec 14, 2027
Sponsor
- Lead sponsor
- NervGen PharmaIndustry
- Sponsor type
- Industry
- First posted
- Sep 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if NVG-291 can improve function in adults with chronic cervical motor-incomplete spinal cord injury. It will also learn about the safety of NVG-291. The main questions it aims to answer are: * Does NVG-291 improve hand function and daily activities? * What side effects do participants have when taking NVG-291? Researchers will compare NVG-291 to a placebo (a look-alike substance that does not contain NVG-291) to see if NVG-291 improves function in adults with chronic cervical motor-incomplete spinal cord injury. Participants will: * Take NVG-291 or a placebo by injection under the skin (subcutaneous) once daily for 12 weeks. * Attend clinic visits for checkups and safety tests. * Complete tests and questionnaires about hand function, walking, daily activities, and quality of life. * Take part in an interview about changes in their condition, within 14 days after the Week 12 visit.
Conditions
- Chronic Spinal Cord Injury
Interventions
NVG-291Drug
NVG-291 is an investigational peptide therapeutic administered by subcutaneous injection. Participants randomized to the experimental arm will receive NVG-291 once daily for 12 weeks. NVG-291 is designed to promote nervous system repair and functional recovery following chronic spinal cord injury.
PlaceboDrug
Matching placebo is supplied as a sterile lyophilized formulation matching NVG-291 in appearance and route of administration. Participants randomized to the placebo arm will receive placebo once daily by subcutaneous injection for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of NVG-291 as measured by change from baseline in combined Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) Quantitative Prehension (QtP) scoreTime frame: Baseline to Week 12
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
NervGen NVG-291-301 Site#104
Birmingham, Alabama · Not yet recruiting
NervGen NVG-291-301 Site# 118
Pheonix, Arizona · Not yet recruiting
NervGen NVG-291-301 Site#109
Downey, California · Not yet recruiting
Craig Hospital
Englewood, Colorado · Recruiting
New England Institue for Clinical Research
Stamford, Connecticut · Recruiting
NervGen NVG-291-301 Site#112
Washington D.C., District of Columbia · Not yet recruiting
NervGen NVG-291-301 Site#107
Miami, Florida · Not yet recruiting
Shepherd Center
Atlanta, Georgia · Recruiting
International Neurorehabilitation Institute
Lutherville, Maryland · Recruiting
NervGen NVG-291-301 Site # 121
Boston, Massachusetts · Not yet recruiting
NervGen NVG-291-301 Site#111
Rochester, Minnesota · Not yet recruiting
NervGen NVG-291-301 Site#115
Camden, New Jersey · Not yet recruiting
NervGen NVG-291-301 Site#117
Paramus, New Jersey · Not yet recruiting
NervGen NVG-291-301 Site#114
West Orange, New Jersey · Not yet recruiting
NervGen NVG-291-301 Site#108
Charlotte, North Carolina · Not yet recruiting
NervGen NVG-291-301 Site# 119
Cleveland, Ohio · Not yet recruiting
NervGen NVG-291-301 Site#116
Philadelphia, Pennsylvania · Not yet recruiting
NervGen NVG-291-301 Site#113
Charleston, South Carolina · Not yet recruiting
NervGen NVG-291-301 Site#110
Houston, Texas · Not yet recruiting
NervGen NVG-291-301 Site# 120
Richmond, Virginia · Not yet recruiting
NervGen NVG-291-301 Site#102
Milwaukee, Wisconsin · Not yet recruiting
NervGen NVG-291-301 Site# 202
Edmonton, Albert, Canada · Not yet recruiting
NervGen NVG-291-301 Site#201
Vancouver, British Columbia, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.